Snapshot from Aug 24, 2026 at 07:00 UTC. For live data and tracking: View Live
Entities / Companies / CytoDyn
Company

CytoDyn

Tracked across 1 events · 6 articles · First seen Apr 20, 2026 · Last active Aug 13, 2026

Sentiment
90
Attention
6
Events
1
Relationships
0
Live sentiment trends, attention charts, and prominence tracking available on the Ergen Dashboard
Events (1)
6 90
Tech
OHSU HIV Newborn Cure Study
Researchers at Oregon Health and Science University (OHSU) published a study in Nature Microbiology showing that a combination of three HIV therapies—neutralizing antibodies, standard antiretroviral therapy, and the experimental monoclonal antibody leronlimab—permanently cleared the virus…
Impact: Leronlimab is a key component of the successful regimen; positive results could boost its clinical prospects and stock value, though human trials are still needed.
Aug 10, 2026 · 6 articles
Key Actions (1)
75 CytoDyn developed leronlimabOHSU HIV Newborn Cure Study
ERGEN INTELLIGENCE
Track CytoDyn live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.